Hangzhou Tigermed Consulting (300347) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.019x

Based on the latest financial reports, Hangzhou Tigermed Consulting (300347) has a cash flow conversion efficiency ratio of 0.019x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥475.40 Million ≈ $69.57 Million USD) by net assets (CN¥24.71 Billion ≈ $3.62 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Hangzhou Tigermed Consulting defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Hangzhou Tigermed Consulting - Cash Flow Conversion Efficiency Trend (2009–2025)

This chart illustrates how Hangzhou Tigermed Consulting's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Hangzhou Tigermed Consulting Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Hangzhou Tigermed Consulting ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
WHITE MTNS INS. GRP DL 1 F:WNI	0.009x
VISTA ENERGY 1 A ADR/1 F:1CIA	N/A
Shinsegae KO:004170	0.029x
CommScope Holding Co Inc NASDAQ:COMM	-0.142x
Texas Capital Bancshares, Inc. NASDAQ:TCBI	0.024x
COWAY Co. Ltd KO:021240	0.002x
Northland Power Inc. TO:NPI	0.113x
Gaon Cable KO:000500	0.025x

Annual Cash Flow Conversion Efficiency for Hangzhou Tigermed Consulting (2009–2025)

The table below shows the annual cash flow conversion efficiency of Hangzhou Tigermed Consulting from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see Hangzhou Tigermed Consulting market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥24.26 Billion ≈ $3.55 Billion	CN¥1.12 Billion ≈ $163.61 Million	0.046x	+1.12%
2024-12-31	CN¥24.06 Billion ≈ $3.52 Billion	CN¥1.10 Billion ≈ $160.53 Million	0.046x	-3.10%
2023-12-31	CN¥24.45 Billion ≈ $3.58 Billion	CN¥1.15 Billion ≈ $168.35 Million	0.047x	-21.40%
2022-12-31	CN¥22.68 Billion ≈ $3.32 Billion	CN¥1.36 Billion ≈ $198.65 Million	0.060x	-13.38%
2021-12-31	CN¥20.61 Billion ≈ $3.02 Billion	CN¥1.42 Billion ≈ $208.35 Million	0.069x	+23.56%
2020-12-31	CN¥17.86 Billion ≈ $2.61 Billion	CN¥998.68 Million ≈ $146.14 Million	0.056x	-41.47%
2019-12-31	CN¥5.52 Billion ≈ $807.94 Million	CN¥527.56 Million ≈ $77.20 Million	0.096x	-40.13%
2018-12-31	CN¥3.27 Billion ≈ $478.82 Million	CN¥522.24 Million ≈ $76.42 Million	0.160x	+41.95%
2017-12-31	CN¥2.80 Billion ≈ $409.92 Million	CN¥314.97 Million ≈ $46.09 Million	0.112x	+7.79%
2016-12-31	CN¥1.84 Billion ≈ $269.22 Million	CN¥191.91 Million ≈ $28.08 Million	0.104x	-40.14%
2015-12-31	CN¥1.07 Billion ≈ $155.98 Million	CN¥185.73 Million ≈ $27.18 Million	0.174x	+265.93%
2014-12-31	CN¥916.90 Million ≈ $134.17 Million	CN¥43.66 Million ≈ $6.39 Million	0.048x	-53.36%
2013-12-31	CN¥755.14 Million ≈ $110.50 Million	CN¥77.10 Million ≈ $11.28 Million	0.102x	+373.15%
2012-12-31	CN¥694.32 Million ≈ $101.60 Million	CN¥14.98 Million ≈ $2.19 Million	0.022x	-91.86%
2011-12-31	CN¥146.03 Million ≈ $21.37 Million	CN¥38.69 Million ≈ $5.66 Million	0.265x	-4.53%
2010-12-31	CN¥95.79 Million ≈ $14.02 Million	CN¥26.59 Million ≈ $3.89 Million	0.278x	-44.03%
2009-12-31	CN¥44.26 Million ≈ $6.48 Million	CN¥21.95 Million ≈ $3.21 Million	0.496x	--

About Hangzhou Tigermed Consulting

SHE:300347 China Diagnostics & Research

Market Cap

$4.33 Billion

CN¥29.60 Billion CNY

Market Cap Rank

#3987 Global

#634 in China

Share Price

CN¥40.12

Change (1 day)

-0.17%

52-Week Range

CN¥36.17 - CN¥69.86

All Time High

CN¥43083.62